GJA9: A Potential Drug Target and Biomarker for Gap Junction Protein Alpha 9

Target Name: GJA9

NCBI ID: G81025

GJA9

GJA9: A Potential Drug Target and Biomarker for Gap Junction Protein Alpha 9

Gap junction protein alpha 9 (GJA9) is a transmembrane protein that plays a critical role in the regulation of cell-cell communication and signaling. It is expressed in various tissues and cell types, including neurons, astrocytes, and pericytes, and is involved in a variety of cellular processes, including cell survival, migration, and synaptic plasticity. GJA9 has also been implicated in a number of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. As such, it is a promising target for new drugs and a diagnostic biomarker.

GJA9 is a protein that is expressed in the brain and is involved in the formation and maintenance of the blood-brain barrier (BBB). The BBB is a specialized barrier that separates the brain from the blood and is responsible for ensuring the delivery of essential nutrients and oxygen to the brain while preventing the entry of harmful substances. GJA9 is a key component of the BBB and is involved in the regulation of the movement of molecules through the barrier.

GJA9 has also been shown to be involved in a number of signaling pathways that are important for brain development and function. For example, GJA9 has been shown to be involved in the Wnt signaling pathway, a pathway that is important for the development and maintenance of the neural tube, which forms the brain and spinal cord. In addition, GJA9 has been shown to be involved in theNotch signaling pathway, a pathway that is important for the regulation of cell proliferation and differentiation.

GJA9 has also been implicated in a number of diseases and conditions, including cancer, neurodegenerative diseases, and autoimmune disorders. For example, GJA9 has been shown to be involved in the development and progression of neurobladder cancer, a type of cancer that is characterized by the formation of tumors in the neurourethra. In addition, GJA9 has been shown to be involved in the development and progression of Alzheimer's disease, a neurodegenerative disorder that is characterized by the progressive loss of brain cells.

In addition to its involvement in disease, GJA9 is also a potential drug target. GJA9 has been shown to be involved in a number of cellular processes that are important for the development and progression of cancer, including the regulation of cell growth, angiogenesis, and the immune response. As such, GJA9 is a potential target for small molecules, antibodies, and other therapeutic agents that can modulate these processes.

GJA9 is also a potential biomarker for a number of diseases and conditions. For example, GJA9 has been shown to be involved in the regulation of cell death, which is an important factor in the development and progression of a variety of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. In addition, GJA9 has been shown to be involved in the regulation of inflammation, which is an important factor in the development and progression of many diseases, including cancer and neurodegenerative diseases.

In conclusion, GJA9 is a protein that is involved in a variety of cellular processes that are important for the development and maintenance of health. As such, it is a promising target for new drugs and a diagnostic biomarker. Further research is needed to fully understand the role of GJA9 in disease and to develop effective therapies and diagnostic tools.

Protein Name: Gap Junction Protein Alpha 9

Functions: One gap junction consists of a cluster of closely packed pairs of transmembrane channels, the connexons, through which materials of low MW diffuse from one cell to a neighboring cell

The "GJA9 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about GJA9 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets